Navigation and service

BIENNIAL REPORT 2019/2020

Welcome

Welcome

Research

Research

International

International

Regulation

Regulation

Organisation

Organisation

Data & Facts

Data & Facts

17.06.2020 back forward

COVID-19 Vaccines: Second Clinical Trial Approved

Spike protein on surface of SARS-CoV-2  (Source: S.Myshkovsky/photodisc/Gettyimages)

The Paul-Ehrlich-Institut approves a second phase I clinical trial for a COVID-19 vaccine candidate in Germany. The mRNA vaccine was developed by the Tübingen company CureVac.